Royalty Pharma PLC (MEX:RPRX)
MXN 528.5 0 (0%) Market Cap: 229.61 Bil Enterprise Value: 416.39 Bil PE Ratio: 10.02 PB Ratio: 1.66 GF Score: 72/100

Royalty Pharma PLC at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 03:50PM GMT
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning. I'm Chris Schott at JPMorgan, and very pleased to be introducing Royalty Pharma today in their first presentation as a public company at the JPMorgan Conference. From the company, we have Pablo Legorreta, the company's founder and CEO. He's going to make some opening remarks about this very unique business, and we'll bring a broader swath of the management team on board for the Q&A.

Also as a reminder, after the presentation, we will have a Q&A session. Anyone who wants to ask a question, please submit those through the Ask a Question button on the screen, and I'll make sure I integrate those into the questions as we go through.

So with that, let me turn the presentation over to Pablo.

Pablo Legorreta
Royalty Pharma plc - Founder, Chairman of the Board & CEO

Thank you, Chris, and good morning, everyone. I have been attending the JPMorgan Healthcare Conference for 24 straight years uninterrupted as an investor from its early days

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot